Imperial College London
Portrait Picture

Professor Shoumitro (Shoumi) Deb

Faculty of Medicine, Department of Brain Sciences

Visiting Professor
 
 
 
//

Contact

 

+44 (0)20 3313 4161s.deb CV

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inbook{Deb:2022,
author = {Deb, S and Roy, M and Limbu, B},
booktitle = {Handbook of Autism and Pervasive Developmental Disorder.},
editor = {Matson and Sturmey},
pages = {1139--1156},
publisher = {Springer Nature Switzerland AG},
title = {Antidepressants.},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - CHAP
AB  - Depressive symptoms are common co-morbidities of Autism Spectrum Disorder (ASD). However, studies of antidepressants haveprimarily assessed their efficacy on ASD core symptoms, particularly repetitive behaviour rather than depression possibly because ofselective serotonin reuptake inhibitors (SSRI) known for their positive effect on the treatment of repetitive behaviour and obsessive compulsive behaviour. Other outcomes have included associated symptoms such as irritability, aggression and other problembehaviours. Most publications are case studies. There were only three randomized controlled trials (RCTs) involving tricyclicantidepressants (two on clomipramine and one on tianeptine) showing an equivocal result and were associated with a high rate ofadverse events. Most placebo controlled RCTs were on SSRIs (13 studies), findings of which are equivocal, some showing somepositive effect and others showing no effect, and some showing more medication related adverse events. Of the three larger studieswith reasonable sample size (over 100 participants), two showed a negative outcome and one showed mixed results. Studies haveinvolved children, adolescents, and adults with ASD. On the basis of the evidence available currently it is difficult to draw anydefinitive conclusion about the effectiveness of antidepressant medications in people with ASD either on the ASD core symptoms orany associated behaviours or symptoms. Therefore, the clinicians must assess possible harm against potential benefit in each casewhen considering using antidepressants in people with ASD.
AU  - Deb,S
AU  - Roy,M
AU  - Limbu,B
EP  - 1156
PB  - Springer Nature Switzerland AG
PY  - 2022///
SP  - 1139
TI  - Antidepressants.
T1  - Handbook of Autism and Pervasive Developmental Disorder.
ER  -
Download